Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.